ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2018

Abstract Number: 1520

DMARD Hepatotoxicity in Rheumatoid Arthritis and Its Association with the Surrogates of Metabolic Syndrome

Abhishek Nandan1, Huzaefah Syed1, Josna Haritha2, David Maniscalco1, Rabia Gill1, Puneet Puri1 and Vivana Rodriguez1, 1Virginia Commonwealth University Health System, Richmond, VA, 2University of Chicago Medicine, Chicago, IL

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: DMARDs, hepatic disorders and rheumatoid arthritis (RA)

Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Hepatotoxicity is a common reason why DMARDs are abandoned or changed in RA. We hypothesize that features of metabolic syndrome (such as obesity, dyslipidemia, and diabetes) are risk factors for DMARD hepatotoxicity in RA.

Methods:   We conducted a retrospective chart review of 361 patients with RA listed as the primary diagnosis code for ≥ 3 consecutive visits. Demographic information, BMI, lipid panel, prior alcohol use, smoking status, viral hepatitis serologies, statin use, seropositive status, and type of DMARD used were recorded at the initial visit. Patients with active hepatitis B and C were excluded from analysis. DMARD hepatotoxicity was defined as change of DMARD or dose decrease of DMARD with corresponding provider documentation of concern for hepatotoxicity. Using exact logistic regression, odds ratios for the risk factors of DMARD hepatotoxicity were calculated.

Results: Out of the 361 patients reviewed: 15.1% had BMI > 35 and 17.8% had a diagnosis of diabetes mellitus II. Table 1 has additional baseline information. 20 of 361 patients (5.5 %) had DMARD hepatotoxicity. Methotrexate (OR 3.07) and leflunomide (OR 6.11) were significantly associated with risk of DMARD hepatotoxicity. Figure 1 demonstrates the adjusted odds ratios for BMI, diabetes, and alcohol abuse as risk factors for DMARD hepatotoxicity. HDL ≤ 40 had an unadjusted OR of 2.98 (0.74 – 12; p 0.119) toward being a risk factor for DMARD hepatotoxicity. RF or anti-CCP seropositivity, statin-use, age, and sex did not demonstrate a correlation value to suggest they are risk factors.

Conclusion: Our study does suggest that several surrogates of metabolic syndrome such as BMI and diabetes mellitus are likely risk factors for development DMARD hepatotoxicity, especially with methotrexate and leflunomide. Though the study was underpowered for the statistical significance on some of these variables, clinicians should consider features of metabolic syndrome as potential risk factors for hepatotoxicity with DMARD use. Further studies need to be performed examining this relationship.


Disclosure: A. Nandan, None; H. Syed, None; J. Haritha, None; D. Maniscalco, None; R. Gill, None; P. Puri, None; V. Rodriguez, None.

To cite this abstract in AMA style:

Nandan A, Syed H, Haritha J, Maniscalco D, Gill R, Puri P, Rodriguez V. DMARD Hepatotoxicity in Rheumatoid Arthritis and Its Association with the Surrogates of Metabolic Syndrome [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/dmard-hepatotoxicity-in-rheumatoid-arthritis-and-its-association-with-the-surrogates-of-metabolic-syndrome/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dmard-hepatotoxicity-in-rheumatoid-arthritis-and-its-association-with-the-surrogates-of-metabolic-syndrome/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology